A Study of Tafetinib in Chinese Patients With Advanced Solid Tumor

NCT02717741 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: tafetinib

Sponsor

Nanjing Yoko Biomedical Co., Ltd.